RCR Romero Castro

R Romero Castro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


R Romero Castro has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Utilidad de la USE-PAAF en el diagnóstico del Cáncer de Páncreas. Experiencia en nuestro centro

    by A Jiménez-García Victoria, R Romero-Castro, F Argüelles-Arias, M Rodríguez-Téllez, J Romero-Vázquez, F Pellicer-Bautista, A Nogales-Muñoz, A Caunedo-Álvarez, M Romero-Gómez, Jm Herrerias

    Introducción: La Ultrasonografía Endoscópica con Punción-Aspiración con Aguja Fina (USE-PAAF) juega un papel importante en el diagnóstico del cáncer de páncreas (CP), con una sensibilidad (S) del 80 – 95% y una especificidad del 75 – 100%. Objetivo: Determinar la utilidad de la PAAF-USE en el diagnóstico del CP en nuestro medio. Material y Métodos: Estudio retrospectivo, unicéntrico y comparativo. Se incluyeron pacientes con sospecha de CP que se realizaron USE-PAAF y posteriormente duodenopancreatectomía cefálica (DPC) entre Febrero/2009 y Junio/2014. Se analizó: edad al diagnóstico (ED), síntomatología, supervivencia, tipo de aguja, presencia/ausencia de células neoplásicas en PAAF y se comparó con el resultado histológico de la pieza quirúrgica (PQ) como gold standard. Resultados: Se incluyeron 30 pacientes con sospecha clínica de CP y ED de 60,76 ± 10,16años. Síntomas predominantes: ictericia (63%), colestasis (60%), síndrome constitucional (53%), dolor abdominal (50%) y diarrea (20%). En 83% se utilizó aguja 25G y en el 17% 22G. En la PQ 29/30 casos fueron neoplasias malignas y un caso resultó patología benigna (Figura 1). En 23/29 casos (79%) la PAAF fue diagnóstica de lesión maligna. En 4 de los 5 casos que se utilizó aguja de 22G la PAAF no fue diagnóstica de malignidad. La supervivencia a 1 año de la DPC fue 42%, a 2 años 41%, a 3 – 4 años 10% y a 5 años 7%. Se calculó S del 76% y VPP del 96% de USE-PAAF en el diagnóstico del CP. Conclusiones: La USE-PAAF es útil en el diagnóstico del CP en nuestro medio con una S similar a la descrita en la literatura. La supervivencia en nuestra serie parecer ser ligeramente superior a lo descrito previamente. Otros factores, como el tipo de aguja empleado, podrían influir en la mejora de resultados; si bien, el reducido número de pacientes impide ser más categóricos en esta afirmación.

  • Endosonographisch gestützte Coil-Applikation vs. Cyanoacrylat-Injektion zur Therapie von Fundusvarizen - eine multizentrische Studie

    by M Ellrichmann, R Romero-Castro, C Ortiz-Moyano, Jc Subtil-Inigo, F Junquera-Florez, Jb Gornal, A Repiso-Ortega, J Vila-Costas, F Marcos-Sanchez, M Munoz-Navas, et al.

    Einleitung: Die Therapie von Fundusvarizen (GV) stellt noch immer eine technische Herausforderung dar. Für die Therapie von blutenden GV wird die Injektion von Cyanoacrylat (CYA) empfohlen. Diese Therapieform birgt eine signifikante Komplikationsrate, die möglicherweise durch den Einsatz der Endosonografie reduziert werden könnte. Zusätzlich könnte eine endosonographisch gesteuerte Coil-Applikation (ECA) eine therapeutische Alternative darstellen. Ziele: Vergleich der endosonographischen CYA-Injektion (E-CYA) vs. ECA zur Therapie von GV in Bezug auf Machbarkeit, Erfolgs- und Komplikationsrate. Methodik: 30 konsekutive Patienten mit lokalisierten GV, die entweder eine CYA-Injektion oder einer ECA erhielten wurden in die Studie eingeschlossen. Über einen Zeitraum von mindestens 6 Monaten wurden die Patienten nachuntersucht. Patientenbezogene Daten, Angaben zur Intervention und Komplikationen wurden prospektiv erhoben und retrospektiv ausgewertet. Unmittelbar nach Intervention erhielten alle Patienten ein Thorax-CT, um mögliche Embolien auszuschließen. Ergebnisse: In der Coil-Gruppe wurden N = 11 Patienten, in der CYA-Gruppe N = 19 eingeschlossen. In 96,7% der Fälle konnten mit beiden Methoden die GV obliteriert werden (E-CYA group = 100% (19/19); ECA = 90,9% (10/11)). Im Mittel wurden 1,4 ± 0,1 (range: 1 – 3) endoskopische Sitzungen benötigt: 29 Sitzungen E-CYA und 14 Sitzungen ECA. Komplikationen traten insgesamt bei 12/30 Patienten (40%) auf (E-CYA: 11/19 = 57,9%; ECA: 1/11 = 9,1%; p < 0,01): von diesen boten nur 3 eine klinische Symptomatik, weitere 9 Patienten (nur E-CYA) zeigten eine Embolisation des CYA in die Lunge, blieben aber asymptomatisch. Weitere Komplikationen traten im Überwachungsintervall nicht auf. 6 Patienten (20%) starben unabhängig von der Intervention oder einer Blutungskomplikation. Schlussfolgerung: Die EUS-gesteuerte Obliteration von GV mittels CYA oder Coils ist eine effektive Therapieoption. Durch eine ECA waren weniger Sitzungen notwendig bei signifikant geringerer Komplikationsrate im Vergleich zur CYA-Injektion. Größere Studien sind notwendig, um diese Daten zu bestätigen. Freie Vorträge: Best of VariaDonnerstag, 12. September 2013/15:00 – 16:40/Stockholm

  • Endoscopic ultrasound (EUS)-guided coil embolization therapy in gastric varices

    by R. Romero-Castro, F. Pellicer-Bautista, M. Giovannini, F. Marcos-Sánchez, C. Caparros-Escudero, M. Jiménez-Sáenz, M. Gomez-Parra, A. Arenzana-Seisdedos, V. Leria-Yebenes, J. M. Herrerias-Gutiérrez

    Bleeding from gastric varices is a life-threatening event, however, there is no global consensus on its optimum treatment. Recently, the use of therapeutic endoscopic ultrasound (EUS) in vascular disorders has been reported [ 1 ] [ 2 ] [ 3 ] [ 4 ] [ 5 ]. Here we report on four patients with severe gastric varices (two patients with Child–Pugh class A, and one each with class B and C; two patients with bleeding) treated with EUS-guided coil embolization. We informed all four patients and their relatives about the experimental nature of the technique and obtained written informed consent. Prophylactic antibiotic therapy was administered and the working channel of the endoscope was flushed with povidone-iodine before the procedure. Under EUS and fluoroscopy guidance, stainless steel, synthetic-fiber coils (MReye; IMWCE, Cook, Limerick, Ireland), of diameter 0.035 inch, straight length 50 – 150 mm, and coiled diameter 8 – 15 mm, were deployed through a 19-gauge needle ([ Fig. 1 ], [ 2 ]). Once the needle was inside the vessel, the stylet was withdrawn and the coil was deployed by advancing the stiffer part of a 0.035 inch guide wire, with the aim of delivering it as coiled as possible. In the first patient, who had a large gastrorenal shunt, we delivered the coils into the gastric varices to prevent migration. After we had placed 13 coils, neither migration nor thrombosis was observed. Therefore we modified the technique to deliver the coils not into the varix but into its perforating feeding vein, and nine additional coils were deployed in the first patient and seven ([ Video 1 ], [ 2 ]), three, and two coils were deployed in the remaining three patients. All the coils were delivered into the perforating feeding vein, with the aim of forming a mesh to block the flow of blood. The diameter of the perforating feeding vein in the four patients was 13 mm, 12 mm, 8 mm, and 6 mm. The coils were selected depending on their expected size once they were coiled, which was approximately 20 % greater that the caliber of the perforating vessels. Fig. 1 a Endoscopic view of gastric varices in the second patient treated with endoscopic ultrasound (EUS)-guided coil embolization therapy. A nasogastric tube is also seen. b EUS view of the gastric varices. c EUS-guided coil (arrows) deployed in the perforating vein of the gastric varices. The 19-gauge needle is seen traversing the diaphragm (asterisk). d The delivered coils formed a thick mesh that blocked the blood flow through the perforating feeding vein of the gastric varices, with downstream flow of the contrast injected through the 19-gauge needle. Note the width of the column of dye (between white arrows) compared with the caliber of the therapeutic echoendoscope. Fig. 2 a Gastric varices reduced to form firm folds on palpation. b Endoscopic ultrasound (EUS) examination showing a thrombosed perforating vein with coils (arrow). Ao, aorta. c EUS examination also showing a gastric wall without varices and with coils with an acoustic shadow. d The thick mesh formed by the seven deployed coils. The gastric varices were eradicated in three of the four patients (75 %). No migration or complications were observed in these three patients on follow up at a mean of 5 months after the procedure (range 1 – 13 months). Although (EUS)-guided coil embolization therapy is a technically demanding procedure, our preliminary experience shows it can be carried out in less than 30 minutes. The overall mortality was 25 %, however, this was not related to the procedure. Larger series are warranted to further evaluate this technique.


  • Esophageal tumor diagnosed by capsule endoscopy

    by A. Sánchez-Yagüe, A. Caunedo-Álvarez, R. Romero-Castro, J. Romero-Vázquez, A. Antúnez-Infante, F. Pellicer-Bautista, J. M. Herrerías-Gutiérrez

    A 74-year-old man was referred to our unit with a 3-year history of typical heartburn symptoms. His heartburn had became refractory to treatment with proton pump inhibitors in the 3 weeks prior to presentation but it was not accompanied by dysphagia, anemia, hematemesis, or weight loss. He was recommended to have an upper gastrointestinal endoscopy but he refused to undergo this examination. After much discussion, he was offered the option of esophageal capsule endoscopy, with the proviso that if any abnormal finding was observed he would require standard upper gastrointestinal endoscopy. The patient swallowed the video capsule (PillCam ESO; Given Imaging, Yoqneam, Israel) without problems and the study lasted for 20 minutes and 23 seconds, during which time the capsule did not pass into stomach (although capsule excretion was confirmed later). The capsule study revealed a polypoid lesion in the mid-esophagus (Figure [ 1 ], Video 1), as well as mucosa distal to the polyp that resembled gastric mucosa and was consistent with a diagnosis of Barrett’s esophagus. Figure 1 Esophageal capsule endoscopy revealed a polypoid lesion with a prominent area of nonbleeding ulceration at its apex (see also Video 1). To investigate the lesion seen in the capsule study further, the patient then underwent upper gastrointestinal endoscopy (Figure [ 2 ]) with biopsy, and endoscopic ultrasonography. The ultrasound examination revealed a mass that arose from the mucosa and infiltrated to the muscular layer. One rounded, echo-poor lymph node, 7 mm in diameter, was observed adjacent to the lesion, so a TNM stage of T2 N1 was established. Histological studies showed pleomorphic cells with large nuclei forming nests with infiltrative borders and necrotic areas. The absence of corneal pearls led to the diagnosis of undifferentiated esophageal carcinoma. Figure 2 Conventional endoscopy confirmed the presence of the polypoid lesion. Preliminary results seem to demonstrate that esophageal capsule endoscopy has a high diagnostic yield in the detection of Barrett’s esophagus and esophageal varices [ 1 ] [ 2 ]. However, to our knowledge, this is the first reported case of an esophageal cancer diagnosed by esophageal capsule endoscopy, highlighting the potential usefulness of this technique for the detection of tumors. Nevertheless, the role of esophageal capsule endoscopy in screening for esophageal cancer must be assessed by well-designed, cost-effective studies. Endoscopy_UCTN_Code_CCL_1AB_2AC_3AB Endoscopy_UCTN_Code_CCL_1AB_2AH_3AB


  • Diagnostic yield and safety of sequential endoscopic ultrasonography (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) in pancreatobiliary disorders

    by C. Ortiz-Moyano, F. J. Pellicer-Bautista, V. Lería-Yébenes, R. Romero-Castro, J. M. Herrerías-Gutiérrez

    Aims: EUS and ERCP are complementary procedures in pancreatobiliary processes (PBD). Our aim was to evaluate the diagnostic yield and safety of both procedures performed in the same endoscopic session. Patients and methods: From October 2004 to February 2006, 39 patients were enrolled in a prospective study. Clinical indications for were jaundice (69%), abdominal pain (25%), cholestasis (2%) and pancreatic fistula (2%). In 20 (51%) patients PBD were suspected by abdominal ultrasound (US) and CT scan without diagnosis whereas 19 (48%) had a definitive diagnosis made by US and CT scan. Mean age was 62.4 years (range 25–94). 29 male and 10 female. Explorations were performed in the endoscopy room under deep sedation and monitorized by an anesthesiologist. All patients were under medical observation 24 hours after exploration. No antibiotics were administered except in one case of fever in a Klatskin's tumor. We used a lineal Pentax® echoendoscope and a Olympus® duodenoscope with a 4.2 millimeters working channel. 22-G needles (GIP-Mediglobe and Wilson-Cook) were used in all cases except in two cases of rendez-vous (19G needle). Results: EUS was first performed in 33 cases (84.61%). EUS-FNA was done in 20 cases (51.28%). Therapeutic ERCP was performed in 27 cases (70%), including 15 stents, 2 biliary drainages, 2 stone removal and 8 sphincterotomies. ERCP was avoided in 12 patients (30.7%) after EUS findings. Final diagnosis were pancreatic adenocarcinoma (11), ampullary tumor (2), papillitis (7), cholangiocarcinoma (6), chronic pancreatitis (3), pancreatic pseudocyst (3), and others (7). No major complications were recorded after 30 days. Conclusions: In our experience, EUS-ERCP is a safe combination allowing diagnosis, staging and treatment of PBD in a single endoscopic session and being EUS the most accurate diagnostic technique avoiding unnecessary ERCPs.

    • 1 January 2002
      • Vol. 94  (1) , 19-24

    Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection.

    by P Hergueta Delgado, M Rojas Feria, R Romero Castro, F J Mendoza Olivares, B Gómez Rodríguez, F J Pellicer Bautista, J M Herrerías Gutiérrez

    Examine the effectiveness of treatments that include ranitidine bismuth citrate (RBC) for Helicobacter pylori infection. Prospective and randomised study. 137 patients were included (62 women, 75 males, average age 46.9 +/- 13) diagnosed with peptic ulcer and infection by Helicobacter pylori. None had received treatment previously. 67 patients were treated with RBC 400 mg bd and clarithromycin 500 mg bd for 14 days, and 70 patients with RBC 400 mg bd, clarithromycin 500 mg bd and amoxycillin 1 g bd for 7 days. The infection eradication was proven eight weeks after treatment end. The efficacy of treatment was evaluated using the intention-to-treat method. The Chisquare test (chi 2) was used for the statistical analysis of data. Infection in 48 out of 67 patients (71.64%) treated with RBC-clarithromycin for 14 days was eradicated, versus 88.57% (62 out of 70) among those treated with RBC-clarithromycin-amoxycillin for 7 days, with a significant difference between both regimens (p < 0.05). 7-day treatment with RBC-clarithromycin-amoxycillin has a good eradication rate (88.57%) and represents a valid alternative to regimens including a PPI and two antibiotics, as both regimens have a similar efficacy. Results obtained with the double therapy of RBC-clarithromycin for 14 days were not satisfactory, the rate of eradication being 71.64%. The use of an RBC treatment for Helicobacter pylori infection should always be accompanied by two antibiotics in a triple therapy.

    • 1 October 2001
      • Vol. 93  (10) , 659-68

    Use of recombinant factor VII in hepatology.

    by R Romero Castro, N Barroso Relinque, A Caunedo Alvarez, J M García Montes, J M Herrerías Gutiérrez

    Understanding the key role of factor VII (FVII) in the cascade of blood coagulation has led to consider its administration as an effective treatment for selected situations with altered haemostasis. Advances in genetic engineering have made it possible to obtain this factor by recombinant techniques (rFVII), rendering it both safe and widely available as a haemostatic treatment. So far, it has been commonly used for haemophilic patients with inhibiting antibodies against factors FVIII-FIX, but its use is currently extending to other areas. The presence of decreased FVII levels in patients with advanced, chronic liver disease has recently raised an interest in the study of this molecule as a new therapeutic option in the field of Hepatology. This paper will discuss the characteristics, indications, and studies existing to this day on the use of rFVII, particularly in cirrhotic patients.

    • 1 October 2001
      • Vol. 93  (10) , 675-6

    A case of bleeding gastric varices treated with recombinant factor VII.

    by R Romero-Castro, M Jiménez-Sáenz, F J Pellicer-Bautista, A Caunedo-Alvarez, N Barroso-Relinque, J M García Montes, J M Herrerías-Gutiérrez

    • 1 December 2000
      • Vol. 92  (12) , 793-8

    Resistance of Helicobacter pylori to antimicrobial treatment in a Seville hospital catchment area.

    by M Rojas Feria, A I Suárez Barrenechea, C Conejo Gonzalo, P Hergueta Delgado, R Romero Castro, J M Herrerías Gutiérrez

    To determine the sensitivity to metronidazol, clarithromycin, amoxicillin and tetracycline of strains of Helicobacter pylori isolated in a prospective series of patients referred to a university hospital in Seville for endoscopic examination. During the period from March 1998 to July 1999 we studied 117 patients with ulcer. The diagnosis of bacterial infection was based on the rapid urease test, histological study, Gram staining or culture of gastric biopsy material (from the antrum and corpus) obtained during gastroscopy. Susceptibility studies were done with the diffusion method using E-test strips. Helicobacter pylori infection was found in 64 patients. A total of 58 strains were grown, 40 of which were from patients who had received no previous treatment to eradicate the infection (69%), and 18 of which were from patients who had failed one or more eradication therapies (31%). In the first group, metronidazol resistance was found in 42%, clarithromycin resistance in 13%, and resistance to both in 10% of the patients. In the second group these rates were 39%, 44% and 17% respectively, and one strain was found which was also resistant to tetracyclines (2%). No strains resistant to amoxicillin were found. We found high rates of resistance, especially to clarithromycin, and especially in patients who had received previous eradication therapy. Empirical treatments should use effective antimicrobials and avoid regimens based on a single antibiotic. Culture of gastric biopsy samples provides information on the resistance to antimicrobials in a given setting, and this information can be used to develop the most rational treatment for the infection.